G-CSF Mobilizes Blood Stem Cells in Cancer Patients
Author Information
Author(s): E. DeLuca, W.P. Sheridan, D. Watson, J. Szer, C.G. Begley
Primary Institution: The Walter and Eliza Hall Institute of Medical Research
Hypothesis
Can G-CSF effectively mobilize peripheral blood progenitor cells in patients who have undergone prior chemotherapy?
Conclusion
G-CSF can successfully mobilize progenitor cells into the peripheral blood even after intensive chemotherapy.
Supporting Evidence
- G-CSF increased the number of peripheral blood progenitor cells by a median of 76-fold.
- Maximal levels of progenitor cells were observed on days 5 and 6 after G-CSF treatment.
- Two patients showed comparable levels of progenitor cells after a second cycle of G-CSF.
Takeaway
This study shows that a medicine called G-CSF can help collect special blood cells from cancer patients, even if they have had strong treatments before.
Methodology
Patients received G-CSF for 6 or 7 days, followed by leukapheresis to collect progenitor cells.
Potential Biases
Potential bias due to the small sample size and patient selection.
Limitations
The study had variability in patient responses due to prior chemotherapy treatments.
Participant Demographics
Patients with non-myeloid malignancies, including acute lymphoblastic leukaemia and non-Hodgkin's lymphoma.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website